Phase II AMG 386 and Paclitaxel Combination Trial

Beth Y. Karlan MD
Published: Tuesday, Apr 26, 2011

Beth Y. Karlan MD Director at Cedars-Sinai Women's Cancer Research Institute Provides an Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial
Beth Y. Karlan MD Director at Cedars-Sinai Women's Cancer Research Institute Provides an Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x